Solid Biosciences Inc. Stock News

Solid Biosciences Inc (NASDAQ: SLDB ) has reported two-year interim efficacy and safety data from the first three patients treated with SGT-001 in the high dose (2E14 vg/kg) cohort as part of IGNITE DMD. Results suggest durable benefit 24-months post-administration of SGT-001 compared to natural history, consistent with results reported at the 12-month and 18-month periods. Data from Patients 4-6 suggest improved motor function at two years post-infusion, against expected … Full story available on Benzinga.com

Solid Biosciences (NASDAQ: SLDB ) reported its Q4 earnings results on Monday, March 14, 2022 at 06:00 AM. Here''s what investors need to know about the announcement. Earnings Solid Biosciences beat estimated earnings by 10.53%, reporting … Full story available on Benzinga.com

Solid Biosciences Inc. (SLDB) delivered earnings and revenue surprises of 15% and 9.26%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Solid Biosciences Inc (NASDAQ: SLDB) has reported two-year interim efficacy and safety data from the first three patients treated with SGT-001 in the high dose (2E14 vg/kg) cohort as part of IGNITE

- 2-year data from first three patients in the high dose (2E14 vg/kg) cohort suggest sustained or improved motor function, pulmonary function and clinically validated patient-reported outcomes compar

Gainers Marygold Companies (NYSE: MGLD ) shares surged 89.4% to close at $4.11 on Friday after dropping 21% on Thursday. TeraWulf Inc. (NASDAQ: WULF ) gained 49.3% to close at $9.51. Guardforce AI Co., Limited (NASDAQ: GFAI ) jumped 45% to settle at $0.7796 after the company agreed to acquire Shenzhen Keweien and Guangzhou Kewei for $10 million. Clearside Biomedical, Inc. (NASDAQ: CLSD ) rose 42.6% to settle at $1.9250 after the company reported better-than-expected Q4 results. Excellon Resources Inc. (NYSE: EXN ) rose 40.8% to close at $1.38 after jumping around 13% on Thursday. Solid Biosciences Inc. (NASDAQ: SLDB ) jumped 37.4% to settle at $1.06. Altamira Therapeutics Ltd. (NASDAQ: CYTO ) shares gained 36.7% to settle at $0.9449. Altamira Therapeutics reported in vitro efficacy data for bentrio nasal spray in protecting against Sars-CoV-2 omicron variant. 4D pharma plc (NASDAQ: LBPS ) shares surged 35.3% to settle at $3.99. Kala Pharmaceuticals, Inc. (NASDAQ: KALA ) gained 33.1% to close at $1.69.

Seelos Therapeutics, Inc. (NASDAQ:SEEL) with the stream of -4.02% also noticed, India Solid Biosciences Inc. (NASDAQ:SLDB) encountered a rapid change of -4.61% in the last hour of Thursday’s trading session. … The post Perspiring Stock: Seelos Therapeutics, Inc. (NASDAQ:SEEL), Solid Biosciences Inc. (NASDAQ:SLDB) appeared first on Stocks Equity .

Solid Biosciences Inc. (NASDAQ:SLDB) with the stream of -2.86% also noticed, India BitNile Holdings, Inc. (AMEX:NILE) encountered a rapid change of -5.32% in the last hour of Tuesdays trading session. The post Investors are upbeat on the prospect of this Stock: Solid Biosciences Inc. (NASDAQ:SLDB), BitNile Holdings, Inc. (AMEX:NILE) appeared first on Stocks Equity .

CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne

CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Joel Schneider, PhD, Chief Operating Officer, and Carl Morris, PhD, Chief Scientific Officer, will participate in a fireside chat at the SVB Leerink 11 th Annual Global Healthcare Conference on Thursday, February 17, 2022 at 4:20 pm ET.

CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne),

Solid Biosciences Inc (SLDB) shares closed today at 1.9% above its 52 week low of $1.55, giving the company a market cap of $174M. The stock is currently down 9.7% year-to-date, down 76.4% over the past 12 months, and down 93.0% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 6.2% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.2. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 3627.6% The company's stock price performance over the past 12 months lags the peer average by 929.9% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Solid Biosciences Inc (SLDB) shares closed today at 1.9% above its 52 week low of $1.55, giving the company a market cap of $174M. The stock is currently down 9.7% year-to-date, down 81.4% over the past 12 months, and down 93.0% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 6.2% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.2. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 3627.6% The company's stock price performance over the past 12 months lags the peer average by 830.0% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

CAMBRIDGE, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne

Solid Biosciences Inc. (SLDB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.